Beranda › Neuropati Sensorik dan Otonom Herediter › Ohio
Uji klinis Neuropati Sensorik dan Otonom Herediter di Ohio
6 studi untuk Neuropati Sensorik dan Otonom Herediter mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Ohio State University, Columbus
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07175038A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- UH Cleveland Medical Center, Cleveland
- Stefanie Spielman Comprehensive Breast Center, Columbus
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
- Oncology Hematology Care Inc, Cincinnati
Menerima pesertaStudi observasional
Usia 1 hingga 100 · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05868629Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- University of Cincinnati Medical Center, Cincinnati
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 24 Des 2025 · NCT06463028The Cancer of the Pancreas Screening-5 CAPS5)Study
- Case Comprehensive Cancer Center, Case Western Medical Reserve, Cleveland
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Okt 2025 · NCT02000089Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.